RecruitingPhase 3NCT07504458
Blood
Acute promyelocytic leukemia
10
studies recruiting now
as of 7 Sept 2026
176
studies registered in total
as of 7 Sept 2026
5
countries with a recruiting site
as of 7 Sept 2026
31 Mar 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1NCT02390752
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
RecruitingPhase 2NCT01409161
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
RecruitingPhase 1NCT02390635
PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
RecruitingPhase 3NCT07503730
Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 10 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Acute promyelocytic leukemia study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Acute promyelocytic leukemia
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (PML, PRKAR1A, RARA, STAT5B, FIP1L1, NPM1).
Treatments being studied
3 approved treatments and 13 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Tretinoin (Acticin)Approved: Arsenic Trioxide (Arsenic trioxide accord)Approved: Gemtuzumab Ozogamicin (Mylotarg)
Phase 3Cytarabine (Alexan)
Phase 3Indigo
Phase 3Hydroxyurea (Droxia)
Phase 2/3Venetoclax (Venclexta)
Phase 2Tucidinostat (Epidaza in china)
Phase 2Gelatin (Gelofusine)
Phase 2Asciminib
Phase 2Ascorbic Acid (Ascor)
+ 5 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).